Patients with CDH1 mutations showed numerically shorter immune-related OS (irOS), compared to those with CDH1 -WT (all cohort: median OS 6.53 vs 8.03 months, HR = 1.24, 95%CI: 0.81–1.88, p = 0.319; MSS cohort: 4.77 vs 6.3 months, HR = 1.23, 95%CI: 0.78–1.93, p = 0.376), although this difference did not reach statistical significance (Fig. 4d , Supplementary Fig. 1b ).
← all excerpts
Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer.
1
—
—